sorafenib has been researched along with fingolimod hydrochloride in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,771 | 157 | 2,062 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashman, LK; Don, AS; Dun, MD; Enjeti, A; Flanagan, H; Guthridge, MA; Harrison, C; Kahl, R; Lee, EM; Lock, RB; Mashkani, B; Moore, A; Morris, J; Panicker, N; Powell, JA; Skelding, KA; Smith, AM; Thomas, D; Toop, H; Verrills, NM | 1 |
| Hino, H; Hiramoto, M; Kazama, H; Lorenzo, A; Miyazawa, K; Moriya, S; Okuma, T; Ota, K; Takano, N; Yokota, A | 1 |
2 other study(ies) available for sorafenib and fingolimod hydrochloride
| Article | Year |
|---|---|
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Topics: Animals; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Phosphatase 2; Sorafenib | 2016 |
Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
Topics: A549 Cells; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2019 |